Levothyroxine Sodium
- Product NDC
- 50090-4951
- 11-digit product format
- 500904951
- Labeler code
- 50090
- Product ID
- 50090-4951_4ba3b2b8-f1a9-4dd0-a88b-f0f7e7e91980
- Type
- HUMAN PRESCRIPTION DRUG
- Nonproprietary name
- Levothyroxine Sodium
- Dosage form
- TABLET
- Route
- ORAL
- Labeler
- A-S Medication Solutions
- Application
- ANDA209713
- Marketing category
- ANDA
- Marketing start
- 2019-03-20
- Substance
- LEVOTHYROXINE SODIUM
- Active strength
- .088 mg/1
- Pharmacologic classes
- Thyroxine [CS], l-Thyroxine [EPC]
- NDC exclude flag
- No
- Listing certified through
- 2026-12-31
- Current FDA listing
- Yes
Observed NDC auxiliary status history#
This history shows the information present in each captured FDA auxiliary file. It is not a continuous regulatory timeline, and a missing record does not establish a status.
| Captured / source date | Dataset | Scope | Package NDC | Snapshot | Source SHA-256 |
|---|---|---|---|---|---|
| 2025-04-01 02:39 UTC · source 2025-03-31 | excluded product | product | 2ef7874e63bc… | 57b86245f4fa… | |
| 2025-04-01 02:39 UTC · source 2025-03-31 | excluded package | package | 50090-4951-1 | 2ef7874e63bc… | 57b86245f4fa… |
| 2025-04-01 02:39 UTC · source 2025-03-31 | excluded package | package | 50090-4951-0 | 2ef7874e63bc… | 57b86245f4fa… |
| 2025-03-28 20:22 UTC · source 2025-03-28 | excluded product | product | a1b67e2a42f9… | c4cf2c586c0d… | |
| 2025-03-28 20:22 UTC · source 2025-03-28 | excluded package | package | 50090-4951-1 | a1b67e2a42f9… | c4cf2c586c0d… |
| 2025-03-28 20:22 UTC · source 2025-03-28 | excluded package | package | 50090-4951-0 | a1b67e2a42f9… | c4cf2c586c0d… |
| 2025-03-22 03:12 UTC · source 2025-03-21 | excluded product | product | cfe11265f3b6… | 090c488252e2… | |
| 2025-03-22 03:12 UTC · source 2025-03-21 | excluded package | package | 50090-4951-1 | cfe11265f3b6… | 090c488252e2… |
| 2025-03-22 03:12 UTC · source 2025-03-21 | excluded package | package | 50090-4951-0 | cfe11265f3b6… | 090c488252e2… |
| 2025-03-10 12:48 UTC · source 2025-03-10 | excluded product | product | cdf11ea48f46… | ba0047e9e063… | |
| 2025-03-10 12:48 UTC · source 2025-03-10 | excluded package | package | 50090-4951-1 | cdf11ea48f46… | ba0047e9e063… |
| 2025-03-10 12:48 UTC · source 2025-03-10 | excluded package | package | 50090-4951-0 | cdf11ea48f46… | ba0047e9e063… |
| 2025-02-02 03:52 UTC · source 2025-01-31 | excluded product | product | 302b2466d912… | e7b80fea0513… | |
| 2025-02-02 03:52 UTC · source 2025-01-31 | excluded package | package | 50090-4951-1 | 302b2466d912… | e7b80fea0513… |
| 2025-02-02 03:52 UTC · source 2025-01-31 | excluded package | package | 50090-4951-0 | 302b2466d912… | e7b80fea0513… |
| 2025-01-20 13:05 UTC · source 2025-01-20 | excluded product | product | ed331223b511… | 672a5bd82f5f… | |
| 2025-01-20 13:05 UTC · source 2025-01-20 | excluded package | package | 50090-4951-1 | ed331223b511… | 672a5bd82f5f… |
| 2025-01-20 13:05 UTC · source 2025-01-20 | excluded package | package | 50090-4951-0 | ed331223b511… | 672a5bd82f5f… |
| 2025-01-11 03:41 UTC · source 2025-01-10 | excluded product | product | 0efc9e666f02… | f202fb6c5f17… | |
| 2025-01-11 03:41 UTC · source 2025-01-10 | excluded package | package | 50090-4951-1 | 0efc9e666f02… | f202fb6c5f17… |
| 2025-01-11 03:41 UTC · source 2025-01-10 | excluded package | package | 50090-4951-0 | 0efc9e666f02… | f202fb6c5f17… |
| 2024-11-09 02:27 UTC · source 2024-11-08 | excluded product | product | ad56d346431e… | cc804d4bbf1e… | |
| 2024-11-09 02:27 UTC · source 2024-11-08 | excluded package | package | 50090-4951-1 | ad56d346431e… | cc804d4bbf1e… |
| 2024-11-09 02:27 UTC · source 2024-11-08 | excluded package | package | 50090-4951-0 | ad56d346431e… | cc804d4bbf1e… |
| 2024-10-04 04:10 UTC · source 2024-10-03 | excluded product | product | 367a005e9d99… | 383a685ebd0f… | |
| 2024-10-04 04:10 UTC · source 2024-10-03 | excluded package | package | 50090-4951-1 | 367a005e9d99… | 383a685ebd0f… |
| 2024-10-04 04:10 UTC · source 2024-10-03 | excluded package | package | 50090-4951-0 | 367a005e9d99… | 383a685ebd0f… |
Orange Book products#
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| A209713-001 | LEVOTHYROXINE SODIUM | LEVOTHYROXINE SODIUM | 0.025MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2019-01-18 | |
| A209713-002 | LEVOTHYROXINE SODIUM | LEVOTHYROXINE SODIUM | 0.05MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2019-01-18 | |
| A209713-003 | LEVOTHYROXINE SODIUM | LEVOTHYROXINE SODIUM | 0.075MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2019-01-18 | |
| A209713-004 | LEVOTHYROXINE SODIUM | LEVOTHYROXINE SODIUM | 0.088MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2019-01-18 | |
| A209713-005 | LEVOTHYROXINE SODIUM | LEVOTHYROXINE SODIUM | 0.1MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2019-01-18 | |
| A209713-006 | LEVOTHYROXINE SODIUM | LEVOTHYROXINE SODIUM | 0.112MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2019-01-18 | |
| A209713-007 | LEVOTHYROXINE SODIUM | LEVOTHYROXINE SODIUM | 0.125MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2019-01-18 | |
| A209713-008 | LEVOTHYROXINE SODIUM | LEVOTHYROXINE SODIUM | 0.137MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2019-01-18 | |
| A209713-009 | LEVOTHYROXINE SODIUM | LEVOTHYROXINE SODIUM | 0.15MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2019-01-18 | |
| A209713-010 | LEVOTHYROXINE SODIUM | LEVOTHYROXINE SODIUM | 0.175MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2019-01-18 | |
| A209713-011 | LEVOTHYROXINE SODIUM | LEVOTHYROXINE SODIUM | 0.2MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2019-01-18 | |
| A209713-012 | LEVOTHYROXINE SODIUM | LEVOTHYROXINE SODIUM | 0.3MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2019-01-18 |
Therapeutic equivalence codes#
| Application-product | TE code |
|---|---|
| A209713-001 | AB1 |
| A209713-001 | AB2 |
| A209713-001 | AB3 |
| A209713-002 | AB1 |
| A209713-002 | AB2 |
| A209713-002 | AB3 |
| A209713-003 | AB1 |
| A209713-003 | AB2 |
| A209713-003 | AB3 |
| A209713-004 | AB1 |
| A209713-004 | AB2 |
| A209713-004 | AB3 |
| A209713-005 | AB1 |
| A209713-005 | AB2 |
| A209713-005 | AB3 |
| A209713-006 | AB1 |
| A209713-006 | AB2 |
| A209713-006 | AB3 |
| A209713-007 | AB1 |
| A209713-007 | AB2 |
| A209713-007 | AB3 |
| A209713-008 | AB1 |
| A209713-008 | AB2 |
| A209713-008 | AB3 |
| A209713-009 | AB1 |
| A209713-009 | AB2 |
| A209713-009 | AB3 |
| A209713-010 | AB1 |
| A209713-010 | AB2 |
| A209713-010 | AB3 |
| A209713-011 | AB1 |
| A209713-011 | AB2 |
| A209713-011 | AB3 |
| A209713-012 | AB1 |
| A209713-012 | AB2 |
| A209713-012 | AB3 |
Observed Orange Book product history#
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-10-15 13:18:30 | 2026-09 | A209713-001 | LEVOTHYROXINE SODIUM | 0.025MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2019-01-18 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | A209713-002 | LEVOTHYROXINE SODIUM | 0.05MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2019-01-18 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | A209713-003 | LEVOTHYROXINE SODIUM | 0.075MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2019-01-18 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | A209713-004 | LEVOTHYROXINE SODIUM | 0.088MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2019-01-18 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | A209713-005 | LEVOTHYROXINE SODIUM | 0.1MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2019-01-18 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | A209713-006 | LEVOTHYROXINE SODIUM | 0.112MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2019-01-18 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | A209713-007 | LEVOTHYROXINE SODIUM | 0.125MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2019-01-18 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | A209713-008 | LEVOTHYROXINE SODIUM | 0.137MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2019-01-18 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | A209713-009 | LEVOTHYROXINE SODIUM | 0.15MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2019-01-18 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | A209713-010 | LEVOTHYROXINE SODIUM | 0.175MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2019-01-18 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | A209713-011 | LEVOTHYROXINE SODIUM | 0.2MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2019-01-18 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | A209713-012 | LEVOTHYROXINE SODIUM | 0.3MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2019-01-18 | c2088c7a36db… | |
| 2026-09-14 22:38:34 | 2026-08 | A209713-001 | LEVOTHYROXINE SODIUM | 0.025MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2019-01-18 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | A209713-002 | LEVOTHYROXINE SODIUM | 0.05MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2019-01-18 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | A209713-003 | LEVOTHYROXINE SODIUM | 0.075MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2019-01-18 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | A209713-004 | LEVOTHYROXINE SODIUM | 0.088MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2019-01-18 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | A209713-005 | LEVOTHYROXINE SODIUM | 0.1MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2019-01-18 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | A209713-006 | LEVOTHYROXINE SODIUM | 0.112MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2019-01-18 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | A209713-007 | LEVOTHYROXINE SODIUM | 0.125MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2019-01-18 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | A209713-008 | LEVOTHYROXINE SODIUM | 0.137MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2019-01-18 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | A209713-009 | LEVOTHYROXINE SODIUM | 0.15MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2019-01-18 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | A209713-010 | LEVOTHYROXINE SODIUM | 0.175MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2019-01-18 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | A209713-011 | LEVOTHYROXINE SODIUM | 0.2MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2019-01-18 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | A209713-012 | LEVOTHYROXINE SODIUM | 0.3MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2019-01-18 | 84e616aacf4f… | |
| 2026-08-18 06:07:40 | 2026-07 | A209713-001 | LEVOTHYROXINE SODIUM | 0.025MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2019-01-18 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | A209713-002 | LEVOTHYROXINE SODIUM | 0.05MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2019-01-18 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | A209713-003 | LEVOTHYROXINE SODIUM | 0.075MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2019-01-18 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | A209713-004 | LEVOTHYROXINE SODIUM | 0.088MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2019-01-18 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | A209713-005 | LEVOTHYROXINE SODIUM | 0.1MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2019-01-18 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | A209713-006 | LEVOTHYROXINE SODIUM | 0.112MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2019-01-18 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | A209713-007 | LEVOTHYROXINE SODIUM | 0.125MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2019-01-18 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | A209713-008 | LEVOTHYROXINE SODIUM | 0.137MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2019-01-18 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | A209713-009 | LEVOTHYROXINE SODIUM | 0.15MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2019-01-18 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | A209713-010 | LEVOTHYROXINE SODIUM | 0.175MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2019-01-18 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | A209713-011 | LEVOTHYROXINE SODIUM | 0.2MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2019-01-18 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | A209713-012 | LEVOTHYROXINE SODIUM | 0.3MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2019-01-18 | caaa826d4ba7… | |
| 2026-02-19 14:30 UTC | 2026-02 | A209713-001 | LEVOTHYROXINE SODIUM | 0.025MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2019-01-18 | 011fe1cb6892… | |
| 2026-02-19 14:30 UTC | 2026-02 | A209713-002 | LEVOTHYROXINE SODIUM | 0.05MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2019-01-18 | 011fe1cb6892… | |
| 2026-02-19 14:30 UTC | 2026-02 | A209713-003 | LEVOTHYROXINE SODIUM | 0.075MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2019-01-18 | 011fe1cb6892… | |
| 2026-02-19 14:30 UTC | 2026-02 | A209713-004 | LEVOTHYROXINE SODIUM | 0.088MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2019-01-18 | 011fe1cb6892… |
Observed Orange Book normalized TE history#
| Captured | Edition | Application-product | TE code | Order | Source SHA-256 |
|---|---|---|---|---|---|
| 2026-10-15 13:18:30 | 2026-09 | A209713-001 | AB1 | 1 | c2088c7a36db… |
| 2026-10-15 13:18:30 | 2026-09 | A209713-001 | AB2 | 2 | c2088c7a36db… |
| 2026-10-15 13:18:30 | 2026-09 | A209713-001 | AB3 | 3 | c2088c7a36db… |
| 2026-10-15 13:18:30 | 2026-09 | A209713-002 | AB1 | 1 | c2088c7a36db… |
| 2026-10-15 13:18:30 | 2026-09 | A209713-002 | AB2 | 2 | c2088c7a36db… |
| 2026-10-15 13:18:30 | 2026-09 | A209713-002 | AB3 | 3 | c2088c7a36db… |
| 2026-10-15 13:18:30 | 2026-09 | A209713-003 | AB1 | 1 | c2088c7a36db… |
| 2026-10-15 13:18:30 | 2026-09 | A209713-003 | AB2 | 2 | c2088c7a36db… |
| 2026-10-15 13:18:30 | 2026-09 | A209713-003 | AB3 | 3 | c2088c7a36db… |
| 2026-10-15 13:18:30 | 2026-09 | A209713-004 | AB1 | 1 | c2088c7a36db… |
| 2026-10-15 13:18:30 | 2026-09 | A209713-004 | AB2 | 2 | c2088c7a36db… |
| 2026-10-15 13:18:30 | 2026-09 | A209713-004 | AB3 | 3 | c2088c7a36db… |
| 2026-10-15 13:18:30 | 2026-09 | A209713-005 | AB1 | 1 | c2088c7a36db… |
| 2026-10-15 13:18:30 | 2026-09 | A209713-005 | AB2 | 2 | c2088c7a36db… |
| 2026-10-15 13:18:30 | 2026-09 | A209713-005 | AB3 | 3 | c2088c7a36db… |
| 2026-10-15 13:18:30 | 2026-09 | A209713-006 | AB1 | 1 | c2088c7a36db… |
| 2026-10-15 13:18:30 | 2026-09 | A209713-006 | AB2 | 2 | c2088c7a36db… |
| 2026-10-15 13:18:30 | 2026-09 | A209713-006 | AB3 | 3 | c2088c7a36db… |
| 2026-10-15 13:18:30 | 2026-09 | A209713-007 | AB1 | 1 | c2088c7a36db… |
| 2026-10-15 13:18:30 | 2026-09 | A209713-007 | AB2 | 2 | c2088c7a36db… |
| 2026-10-15 13:18:30 | 2026-09 | A209713-007 | AB3 | 3 | c2088c7a36db… |
| 2026-10-15 13:18:30 | 2026-09 | A209713-008 | AB1 | 1 | c2088c7a36db… |
| 2026-10-15 13:18:30 | 2026-09 | A209713-008 | AB2 | 2 | c2088c7a36db… |
| 2026-10-15 13:18:30 | 2026-09 | A209713-008 | AB3 | 3 | c2088c7a36db… |
| 2026-10-15 13:18:30 | 2026-09 | A209713-009 | AB1 | 1 | c2088c7a36db… |
| 2026-10-15 13:18:30 | 2026-09 | A209713-009 | AB2 | 2 | c2088c7a36db… |
| 2026-10-15 13:18:30 | 2026-09 | A209713-009 | AB3 | 3 | c2088c7a36db… |
| 2026-10-15 13:18:30 | 2026-09 | A209713-010 | AB1 | 1 | c2088c7a36db… |
| 2026-10-15 13:18:30 | 2026-09 | A209713-010 | AB2 | 2 | c2088c7a36db… |
| 2026-10-15 13:18:30 | 2026-09 | A209713-010 | AB3 | 3 | c2088c7a36db… |
| 2026-10-15 13:18:30 | 2026-09 | A209713-011 | AB1 | 1 | c2088c7a36db… |
| 2026-10-15 13:18:30 | 2026-09 | A209713-011 | AB2 | 2 | c2088c7a36db… |
| 2026-10-15 13:18:30 | 2026-09 | A209713-011 | AB3 | 3 | c2088c7a36db… |
| 2026-10-15 13:18:30 | 2026-09 | A209713-012 | AB1 | 1 | c2088c7a36db… |
| 2026-10-15 13:18:30 | 2026-09 | A209713-012 | AB2 | 2 | c2088c7a36db… |
| 2026-10-15 13:18:30 | 2026-09 | A209713-012 | AB3 | 3 | c2088c7a36db… |
| 2026-09-14 22:38:34 | 2026-08 | A209713-001 | AB1 | 1 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | A209713-001 | AB2 | 2 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | A209713-001 | AB3 | 3 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | A209713-002 | AB1 | 1 | 84e616aacf4f… |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.
Additional Listing Data#
- Finished product
- Yes
- Brand name base
- Levothyroxine Sodium
- Listing expiration
- 2026-12-31
Active Ingredients#
| Ingredient | Strength |
|---|---|
| LEVOTHYROXINE SODIUM | .088 mg/1 |
Harmonized UNII identifiers#
| Identifier | FDA.report destination |
|---|---|
| 9J765S329G | Internal UNII lookup |
Harmonized RxCUI identifiers#
| Identifier | FDA.report destination |
|---|---|
| 966253 | Internal RxNorm lookup |
Harmonized SPL set identifiers#
| Identifier | FDA.report destination |
|---|---|
| 7f8ec438-8ddf-45d2-be94-ac032e192229 | Available on FDA.report |
DailyMed Product Concepts#
FDA-Initiated Inactive NDC Indexing#
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 50090-4951-0 | Levothyroxine Sodium | 30 in 1 BOTTLE | TABLET | 30 | 9 | |
| 50090-4951-1 | Levothyroxine Sodium | 90 in 1 BOTTLE | TABLET | 90 | 9 |
DailyMed Billing Units#
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 50090-4951-0 | EA - Each | 50090-4951 | 5a13119d-5940-4775-8f25-98160b2ffc5b | 1 | 2025-06-13 |
| 50090-4951-1 | EA - Each | 50090-4951 | ac0f3312-1927-4b25-ade5-81914e9aec80 | 1 | 2025-06-13 |
DailyMed Dashboard NDC Coverage#
| NDC | Dashboard title | SPL version | Validation | Dashboard ZIP |
|---|---|---|---|---|
| 50090-4951 | LEVOTHYROXINE SODIUM TABLET [A-S MEDICATION SOLUTIONS] | 9 | Current NDC, Legacy NDC, 2 package rows | 20250521_7f8ec438-8ddf-45d2-be94-ac032e192229.zip |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Levothyroxine Sodium | LEVOTHYROXINE SODIUM | A-S Medication Solutions | 3e77de84-6f59-40ac-a1a4-7bfe30387823 | 2023-12-12 | Boxed warning, Warnings, Adverse reactions | 209713 ANDA209713 |
DailyMed RxNorm Mappings#
| RxCUI | RxNorm string | TTY | DailyMed | SPL version |
|---|---|---|---|---|
| 966253 | levothyroxine sodium 88 MCG Oral Tablet | PSN | 7f8ec438-8ddf-45d2-be94-ac032e192229 | 9 |
| 966253 | levothyroxine sodium 0.088 MG Oral Tablet | SCD | 7f8ec438-8ddf-45d2-be94-ac032e192229 | 9 |
| 966253 | levothyroxine sodium 88 MCG Oral Tablet | SY | 7f8ec438-8ddf-45d2-be94-ac032e192229 | 9 |
Packages#
| Package NDC | 11-digit format | Description | Units | Marketing start | Marketing end | Sample | Exclude flag | Status |
|---|---|---|---|---|---|---|---|---|
| 50090-4951-0 | 50090495100 | 30 TABLET in 1 BOTTLE (50090-4951-0) | 30 tablet | 2020-03-02 | 0000-00-00 | No | No | Current |
| 50090-4951-1 | 50090495101 | 90 TABLET in 1 BOTTLE (50090-4951-1) | 90 tablet | 2020-03-02 | 0000-00-00 | No | No | Current |